The ovidrel or ovitrelle market research report is one of a series of new reports that provides ovidrel or ovitrelle market statistics, including the ovidrel or ovitrelle industry global market size, regional shares, competitors with the ovidrel or ovitrelle market share, detailed ovidrel or ovitrelle market segments, market trends, and opportunities, and any further data you may need to thrive in the ovidrel or ovitrelle industry. This ovidrel or ovitrelle market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to improved accessibility to fertility clinics, rapid development of healthcare infrastructure, increase in the rate of hypogonadism-related disorders, growing investment in fertility research, and rising geriatric population. Major trends in the forecast period include rising demand for personalized fertility treatments, increasing focus on minimally invasive drug delivery, the emergence of biosimilars, the development of combination therapies, and advances in hormone-free or alternative fertility treatments.
The growing infertility rates are expected to drive the expansion of the Ovidrel or Ovitrelle market in the coming years. Infertility refers to the inability of individuals or couples to conceive after a year of regular, unprotected intercourse. This trend is influenced by factors such as delayed childbearing, lifestyle choices such as obesity and stress, and environmental factors. Ovidrel or Ovitrelle aids infertility treatments by promoting ovulation through recombinant human chorionic gonadotropin (hCG), which helps release eggs for successful conception. For example, in February 2024, the UK’s Office for National Statistics reported that the total infertility rate increased to 1.49 children per woman in 2022, compared to 1.55 in 2021. As infertility rates rise, the demand for Ovidrel or Ovitrelle is expected to grow.
The increasing prevalence of polycystic ovary syndrome (PCOS) is another key factor driving the growth of the Ovidrel or Ovitrelle market. PCOS is a hormonal disorder that leads to irregular menstrual cycles, ovarian cysts, and higher androgen levels, often resulting in infertility and other metabolic issues. The rise in PCOS cases is linked to factors such as obesity, lifestyle changes, and improved awareness and diagnosis. Ovidrel or Ovitrelle is particularly beneficial for women with PCOS, as it stimulates ovulation, helping to release mature eggs and improve the chances of conception during fertility treatments. According to a June 2023 report from the World Health Organization (WHO), PCOS affects approximately 8-13% of women of reproductive age, with up to 70% of cases going undiagnosed. As PCOS prevalence increases, so too does the demand for Ovidrel or Ovitrelle.
The rising healthcare expenditure is also significantly contributing to the growth of the Ovidrel or Ovitrelle market. Healthcare expenditure refers to the financial resources allocated for medical services, treatments, and healthcare products. The growth in healthcare spending is driven by factors such as aging populations, the increased prevalence of chronic and infectious diseases, advancements in medical technology, and higher demand for quality healthcare. As healthcare expenditures rise, access to fertility treatments improves, making it easier for women, especially those with PCOS, to afford medications such as Ovidrel or Ovitrelle. This support enhances the chances of successful ovulation and improved fertility outcomes. For example, a report from the UK’s Office for National Statistics in May 2024 revealed a 5.6% increase in healthcare expenditure between 2022 and 2023, a significant rise compared to the 0.9% growth in 2022. This increase in healthcare spending is driving the growth of the Ovidrel or Ovitrelle market.
The key companies operating in the ovidrel or ovitrelle market are Merck KGaA, Eli Lilly and Company.
North America was the largest region in the ovidrel or ovitrelle market in 2024. The regions covered in ovidrel or ovitrelle report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the ovidrel or ovitrelle market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Ovidrel, also known as Ovitrelle, is a prescription medication that contains choriogonadotropin alfa, a synthetic form of the hormone human chorionic gonadotropin (hCG). It is primarily used in fertility treatments to trigger ovulation or support the luteal phase in women undergoing assisted reproductive technologies (ART). Ovidrel aids in maturing eggs after ovarian stimulation and can also induce ovulation in women with conditions such as polycystic ovary syndrome (PCOS).
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Ovidrel or Ovitrelle is available in two main formulations, pre-filled syringes and vials. The pre-filled syringes provide a convenient, ready-to-use, single-dose medication for home injections, ensuring precise dosing and reducing the risk of contamination in fertility treatments. The medication is used for various indications, including ART and ovulation induction, and is distributed through multiple channels such as hospitals, clinics, retail pharmacies, and online pharmacies.
The ovidrel or ovitrelle market consists of sales of cartridges, auto-injectors, and pen devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to improved accessibility to fertility clinics, rapid development of healthcare infrastructure, increase in the rate of hypogonadism-related disorders, growing investment in fertility research, and rising geriatric population. Major trends in the forecast period include rising demand for personalized fertility treatments, increasing focus on minimally invasive drug delivery, the emergence of biosimilars, the development of combination therapies, and advances in hormone-free or alternative fertility treatments.
The growing infertility rates are expected to drive the expansion of the Ovidrel or Ovitrelle market in the coming years. Infertility refers to the inability of individuals or couples to conceive after a year of regular, unprotected intercourse. This trend is influenced by factors such as delayed childbearing, lifestyle choices such as obesity and stress, and environmental factors. Ovidrel or Ovitrelle aids infertility treatments by promoting ovulation through recombinant human chorionic gonadotropin (hCG), which helps release eggs for successful conception. For example, in February 2024, the UK’s Office for National Statistics reported that the total infertility rate increased to 1.49 children per woman in 2022, compared to 1.55 in 2021. As infertility rates rise, the demand for Ovidrel or Ovitrelle is expected to grow.
The increasing prevalence of polycystic ovary syndrome (PCOS) is another key factor driving the growth of the Ovidrel or Ovitrelle market. PCOS is a hormonal disorder that leads to irregular menstrual cycles, ovarian cysts, and higher androgen levels, often resulting in infertility and other metabolic issues. The rise in PCOS cases is linked to factors such as obesity, lifestyle changes, and improved awareness and diagnosis. Ovidrel or Ovitrelle is particularly beneficial for women with PCOS, as it stimulates ovulation, helping to release mature eggs and improve the chances of conception during fertility treatments. According to a June 2023 report from the World Health Organization (WHO), PCOS affects approximately 8-13% of women of reproductive age, with up to 70% of cases going undiagnosed. As PCOS prevalence increases, so too does the demand for Ovidrel or Ovitrelle.
The rising healthcare expenditure is also significantly contributing to the growth of the Ovidrel or Ovitrelle market. Healthcare expenditure refers to the financial resources allocated for medical services, treatments, and healthcare products. The growth in healthcare spending is driven by factors such as aging populations, the increased prevalence of chronic and infectious diseases, advancements in medical technology, and higher demand for quality healthcare. As healthcare expenditures rise, access to fertility treatments improves, making it easier for women, especially those with PCOS, to afford medications such as Ovidrel or Ovitrelle. This support enhances the chances of successful ovulation and improved fertility outcomes. For example, a report from the UK’s Office for National Statistics in May 2024 revealed a 5.6% increase in healthcare expenditure between 2022 and 2023, a significant rise compared to the 0.9% growth in 2022. This increase in healthcare spending is driving the growth of the Ovidrel or Ovitrelle market.
The key companies operating in the ovidrel or ovitrelle market are Merck KGaA, Eli Lilly and Company.
North America was the largest region in the ovidrel or ovitrelle market in 2024. The regions covered in ovidrel or ovitrelle report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the ovidrel or ovitrelle market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Ovidrel, also known as Ovitrelle, is a prescription medication that contains choriogonadotropin alfa, a synthetic form of the hormone human chorionic gonadotropin (hCG). It is primarily used in fertility treatments to trigger ovulation or support the luteal phase in women undergoing assisted reproductive technologies (ART). Ovidrel aids in maturing eggs after ovarian stimulation and can also induce ovulation in women with conditions such as polycystic ovary syndrome (PCOS).
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Ovidrel or Ovitrelle is available in two main formulations, pre-filled syringes and vials. The pre-filled syringes provide a convenient, ready-to-use, single-dose medication for home injections, ensuring precise dosing and reducing the risk of contamination in fertility treatments. The medication is used for various indications, including ART and ovulation induction, and is distributed through multiple channels such as hospitals, clinics, retail pharmacies, and online pharmacies.
The ovidrel or ovitrelle market consists of sales of cartridges, auto-injectors, and pen devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Ovidrel Or Ovitrelle Market Characteristics4. Ovidrel Or Ovitrelle Market Trends And Strategies5. Ovidrel Or Ovitrelle Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Ovidrel Or Ovitrelle Pricing Analysis & Forecasts30. Global Ovidrel Or Ovitrelle Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Ovidrel Or Ovitrelle Market32. Recent Developments In The Ovidrel Or Ovitrelle Market
3. Ovidrel Or Ovitrelle Market Biologic Drug Characteristics
6. Global Ovidrel Or Ovitrelle Growth Analysis And Strategic Analysis Framework
8. Ovidrel Or Ovitrelle Market Segmentation
9. Global Ovidrel Or Ovitrelle Epidemiology Of Clinical Indications
10. Ovidrel Or Ovitrelle Market Regional And Country Analysis
11. Asia-Pacific Ovidrel Or Ovitrelle Market
12. China Ovidrel Or Ovitrelle Market
13. India Ovidrel Or Ovitrelle Market
14. Japan Ovidrel Or Ovitrelle Market
15. Australia Ovidrel Or Ovitrelle Market
16. South Korea Ovidrel Or Ovitrelle Market
17. Western Europe Ovidrel Or Ovitrelle Market
18. UK Ovidrel Or Ovitrelle Market
19. Germany Ovidrel Or Ovitrelle Market
20. France Ovidrel Or Ovitrelle Market
21. Eastern Europe Ovidrel Or Ovitrelle Market
22. North America Ovidrel Or Ovitrelle Market
23. USA Ovidrel Or Ovitrelle Market
24. Canada Ovidrel Or Ovitrelle Market
25. South America Ovidrel Or Ovitrelle Market
26. Middle East Ovidrel Or Ovitrelle Market
27. Africa Ovidrel Or Ovitrelle Market
28. Ovidrel Or Ovitrelle Market Competitive Landscape And Company Profiles
29. Global Ovidrel Or Ovitrelle Market Pipeline Analysis
33. Ovidrel Or Ovitrelle Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Ovidrel Or Ovitrelle Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on ovidrel or ovitrelle market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for ovidrel or ovitrelle ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ovidrel or ovitrelle market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Formulation: Pre-Filled Syringes; Vials2) By Indication: Assisted Reproductive Technology (ART); Ovulation Induction
3) By Distribution Channel: Hospitals And Clinics; Retail Pharmacies; Online Pharmacies
Key Companies Profiled: Merck KGaA; Eli Lilly and Company
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck KGaA
- Eli Lilly and Company